Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for...
Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
While the development of elevated blood pressure and proteinuria was associated with favorable outcome of Atez/Bev [3], a cautious interpretation is required due to potential inclusion of lead-time bias when the relationship between AEs and clinical outcome was analyzed. [...]there is a difference in the evaluation method regarding the impact of be...
Alternative Titles
Full title
Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3147125603
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3147125603
Other Identifiers
ISSN
2235-1795
E-ISSN
1664-5553
DOI
10.1159/000538580
